Center-Authored Papers

Filters: Author is Thompson, Ian M  [Clear All Filters]
2008
Thompson IM, Tangen CM, Lucia SM.  2008.  The Prostate Cancer Prevention Trial and the future of chemoprevention.. BJU international. 101(8):933-4.
Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, Thompson IM.  2008.  Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.. American journal of epidemiology. 167(8):925-34. Abstract
Redman MW, Tangen CM, Goodman PJ, Lucia SM, Coltman CA, Thompson IM.  2008.  Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.. Cancer prevention research (Philadelphia, Pa.). 1(3):174-81. Abstract
Thompson IM, Tangen CM, Ankerst DP, Chi C, Lucia SM, Goodman P, Parnes H, Coltman CA.  2008.  The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.. The Journal of urology. 180(2):544-7. Abstract
Sokoll LJ, Wang Y, Feng Z, Kagan J, Partin AW, Sanda MG, Thompson IM, Chan DW.  2008.  [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.. The Journal of urology. 180(2):539-43;discussion543. Abstract
Swanson GP, Goldman B, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford DE.  2008.  The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794.. The Journal of urology. 180(6):2453-7;discussion2458. Abstract
Kristal AR, Schenk JM, Song YJ, Arnold KB, Neuhouser ML, Goodman PJ, Lin DW, Stanczyk FZ, Thompson IM.  2008.  Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.. American journal of epidemiology. 168(12):1416-24. Abstract
Pepe MS, Feng Z, Huang Y, Longton G, Prentice RL, Thompson IM, Zheng Y.  2008.  Integrating the predictiveness of a marker with its performance as a classifier.. American journal of epidemiology. 167(3):362-8. Abstract
Song YJ, Tangen CM, Goodman P, Parnes HL, Lucia SM, Thompson IM, Kristal AR.  2008.  Finasteride, prostate cancer, and weight gain: evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatment.. The Prostate. 68(3):281-6. Abstract
McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, Chan DW, Diaz J, Izbicka E, Kagan J et al..  2008.  Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.. Clinical chemistry. 54(1):44-52. Abstract
McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J et al..  2008.  SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer.. Clinical chemistry. 54(1):53-60. Abstract
Moinpour CM, Hayden KA, Unger JM, Thompson IM, Redman MW, Canby-Hagino ED, Higgins BA, Sullivan JW, Lemmon D, Breslin S et al..  2008.  Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(1):112-20. Abstract
Thompson IM, Tangen CM, Parnes HL, Lippman SM, Coltman CA.  2008.  Does the level of prostate cancer risk affect cancer prevention with finasteride? Urology. 71(5):854-7. Abstract
Thompson IM, Tangen CM, Kristal AR.  2008.  Prostate-specific antigen: a misused and maligned prostate cancer biomarker.. Journal of the National Cancer Institute. 100(21):1487-8.
Thompson IM, Ankerst DP, Etzioni R, Wang T.  2008.  It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer.. The Journal of urology. 180(4):1219-22.
Neuhouser ML, Schenk J, Song YJ, Tangen CM, Goodman PJ, Pollak M, Penson DF, Thompson IM, Kristal AR.  2008.  Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial.. The Prostate. 68(13):1477-86. Abstract
2009
Thompson IM, Tangen CM, Goodman PJ, Lucia SM, Klein EA.  2009.  Chemoprevention of prostate cancer.. The Journal of urology. 182(2):499-507;discussion508. Abstract
Gong Z, Kristal AR, Schenk JM, Tangen CM, Goodman PJ, Thompson IM.  2009.  Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention Trial.. Cancer. 115(16):3661-9. Abstract
Lippman SM, Klein EA, Goodman PJ, Lucia SM, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano MJ, Hartline JA et al..  2009.  Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).. JAMA : the journal of the American Medical Association. 301(1):39-51. Abstract
Thompson IM, Tangen CM, Paradelo J, Lucia SM, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G et al..  2009.  Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.. The Journal of urology. 181(3):956-62. Abstract
Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Thompson IM, Kristal AR.  2009.  Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 18(11):2807-13. Abstract
Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Thompson IM.  2009.  Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.. The Prostate. 69(12):1303-11. Abstract
2010
Price DK, Chau CH, Till C, Goodman PJ, Baum CE, Ockers SB, English BC, Minasian L, Parnes HL, Hsing AW et al..  2010.  Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial.. The Journal of urology. 184(6):2297-302. Abstract
Goodman PJ, Tangen CM, Kristal AR, Thompson IM, Lucia SM, Platz EA, Figg WD, Hoque A, Hsing A, Neuhouser ML et al..  2010.  Transition of a clinical trial into translational research: the prostate cancer prevention trial experience.. Cancer prevention research (Philadelphia, Pa.). 3(12):1523-33. Abstract
Newcomb LF, Brooks JD, Carroll PR, Feng Z, Gleave ME, Nelson PS, Thompson IM, Lin DW.  2010.  Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository.. Urology. 75(2):407-13. Abstract